Clinical trial
Multicentre Open-Label Single Ascending Dose Dose-Ranging Phase I/IIa Study to Evaluate Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor TRegulatory Cell Therapy in Living Donor Renal Transplant Recipients
NCT04817774 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicentre Open-Label Single Ascending Dose Dose-Ranging Phase I/IIa Study to Evaluate Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor TRegulatory Cell Therapy in Living Donor Renal Transplant Recipients
- Lead sponsor
- Sangamo Therapeutics
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 17, 2021
- Completion date
- October 16, 2025
- Enrollment
- 26 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
end stage renal disease, kidney transplant rejection